Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion
Bayer has landed an accelerated US approval for its non-small cell lung cancer (NSCLC) therapy, Hyrnuo (sevabertinib), expanding the drug’s…
10 Sep 2026
HHS appoints permanent FDA CBER, CDER heads
The US Department of Health and Human Services (HHS) has selected four senior leaders to assume permanent positions in the US Food and Drug Administration (FDA), bringing some respite to…
10 Sep 2026
Solstice Oncology secures $225m to drive porustobart’s development for cancer
Harbour BioMed’s partner Solstice Oncology has raised $225m in funding to advance its lead candidate, porustobart, a neoadjuvant immuno-oncology therapy. The financing was raised in a Series A round led…
10 Sep 2026
TwoStep Therapeutics raises $62.5m in funding to advance TS-104
TwoStep Therapeutics has raised $62.5m in an oversubscribed Series A financing round to support its lead peptide-drug conjugate, TS-104, for the treatment of solid tumours. Insight Partners and Medical Excellence…
09 Sep 2026
Why China’s rise needs to be taken with a pinch of salt
A closer look at the numbers that paint China as accelerating towards global biopharma dominance and you will find indications that the region's ascension is not as unassailable as many…
09 Sep 2026
Pharma’s R&D, commercial approach shifts amid global policy evolution
A new report from business management consultancy, Numerof & Associates has found that pharma executives are increasingly rethinking the launch of high-priced, speciality products outside of the US amid a…
09 Sep 2026
Moonwalk banks $70m to progress siRNA therapy for obesity
Moonwalk Biosciences has secured $70m in an oversubscribed, Eli Lilly-backed funding round to take its non-incretin obesity candidate to the clinic. Through this Series B financing, which was co-led by…